New 'Smart' cancer drug seeks to target tumors without harsh side effects
Disease control
Ongoing
This is an early-stage study to test the safety and find the right dose of a new investigational drug called ORB-011 for people with advanced solid tumors. The drug is designed to activate a powerful immune signal only inside specific immune cells near the tumor, aiming to fight …
Phase: PHASE1 • Sponsor: Orionis Biosciences Inc • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC